Trends in the use of administrative databases in urologic oncology: 2000–2019

• Published in: Urologic oncology 2021-08, Vol.39 (8), p.487-492
• Main Authors: Leopold, Zev, Dave, Priya, Menon, Adarsh, Patel, Hiren V., Srivastava, Arnav, Kim, Isaac Y., Jang, Thomas L., Singer, Eric A.
• Format: Article
• Language: English
• Subjects: Administrative databases; Databases, Factual - statistics & numerical data; Databases, Factual - trends; Humans; Periodicals as Topic - statistics & numerical data; Publications - trends; Quality Improvement; Research Design; Trends; Urologic Neoplasms - diagnosis; Urologic Neoplasms - therapy; Urologic oncology
• ISSN: 1078-1439; 1873-2496
• DOI: 10.1016/j.urolonc.2021.01.014

•Utilization of administrative databases for research in urology has increased dramatically.•Prostate, kidney, and bladder are the most common malignancies studied using administrative databases.•Surveillance, epidemiology, and end results is the most frequently used database in urology. Administrative databases (AD) provide investigators with nationally representative study populations to answer research questions using large sample sizes. We aimed to quantify the trends and incidence of AD use in published manuscripts in urologic oncology. We examined 6 commonly used databases: National Cancer Database, surveillance, epidemiology, and end results database (SEER), SEER-Medicare, Nationwide Inpatient Sample, National Surgical Quality Improvement Program, and Premier Healthcare Database. A literature review, powered by PubMed and DistillerSR, aggregated manuscripts that used the aforementioned databases to study a genitourinary malignancy between July 1, 2000 through June 30, 2019. Included publications were categorized by database used, corresponding author department affiliation, organ, journal, year, and contribution – defined as temporal treatment trends, outcomes and survival, comparative effectiveness research, or cost-effectiveness. There were 2,265 publications across 302 journals that met the inclusion criteria. Between 2000 and 2019 the compound annual growth rate of these publications was 18.7%. SEER use grew at a rate of 14.6% annually. National Cancer Database use grew 28.2% annually. Prostate cancer comprised the majority of publications (51.3%), followed by kidney (23.1%) and bladder (22.5%) cancer. Journals publishing these manuscripts had a median impact factor of 3.28 (IQR = 1.84–5.74) in 2019. Urologists published 52.5% of AD manuscripts over the study period. Our results show substantial growth in the use of ADs for the study of urologic oncology. Given the broad use of ADs, investigators and specialty societies should advocate for continued improvement in the data captured by them. [Display omitted]